JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy

NCT05164848 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Carcinoma

Interventions

DRUG: JMT101
DRUG: Afatinib

Sponsor

Peking University